The forecast for Genito Urinary System and Sex Hormones sales in Italy indicates a declining trend from 2024 to 2028, starting at 384.4 million USD in 2024 and decreasing to 285.0 million USD by 2028. This downward trajectory represents a significant contraction in the market, suggesting a year-on-year decrease.

Future trends to observe include:

Potential market shifts due to changes in healthcare policies or regulations in Italy.
Innovation in treatments or introduction of new therapies impacting sales dynamics.
Aging population affecting demand for certain genito-urinary and hormonal therapies.
Economic factors influencing pharmaceutical spending and healthcare budgets.